Myriocin: Selective Serine Palmitoyltransferase Inhibitor

Executive Summary. Myriocin selectively inhibits serine palmitoyltransferase, the enzyme that catalyzes the initial and rate-limiting step of de novo sphingolipid biosynthesis, according to the product information. The reported inhibition constant is Ki = 0.28 nM in the stated assay, although the product page does not specify the assay buffer, temperature, or incubation time. Myriocin inhibits growth of A549 and NCI-H460 lung cancer cells with reported IC50 values of 30 μM and 26 μM, respectively, under product-reported cell-assay conditions whose exposure duration is not specified. The compound has the molecular formula C21H39NO6 and a reported molecular weight of 401.54 g/mol in chemical-identity records. In a rat cardiopulmonary bypass model, myriocin treatment reduced postoperative cognitive dysfunction and normalized hippocampal lipid disturbances in the cited spatial-metabolomics study.

Biological Rationale

Sphingolipids are membrane-associated metabolites with roles in cell structure, signaling, trafficking, stress responses, and programmed cell behavior. De novo sphingolipid biosynthesis begins when serine palmitoyltransferase condenses serine with a fatty-acyl substrate. SPT therefore controls entry into a major biosynthetic pathway.

Blocking SPT reduces the formation of newly synthesized sphingoid-base intermediates and downstream sphingolipids. This makes myriocin useful for testing whether a phenotype depends on de novo sphingolipid production rather than on unrelated signaling events. The compound is consequently used in sphingolipid metabolism research and in studies of proliferation, immune responses, neuronal lipid homeostasis, and stress signaling.

The biological rationale is pathway-focused rather than disease-specific. A change observed after myriocin treatment can indicate SPT-dependent metabolism, but it does not by itself identify the downstream lipid species or establish a single molecular cause. Orthogonal lipid measurements and pathway controls are needed when interpreting complex phenotypes.

Mechanism of Action of Myriocin

Myriocin is a potent and selective serine palmitoyltransferase inhibitor. Its reported Ki of 0.28 nM is a biochemical potency value, not a universal concentration for cell treatment. Ki describes inhibitor binding or functional inhibition in a defined enzyme assay. Cellular IC50 values also depend on uptake, protein binding, metabolism, cell density, exposure time, and assay endpoint.

SPT inhibition suppresses de novo sphingolipid production. The resulting metabolic shift can alter membrane composition and signaling outputs. These changes provide a mechanistic basis for the reported immunosuppressive and antiproliferative activities of myriocin, but downstream effects should be measured rather than assumed.

In cancer research, the product dossier reports dose-dependent inhibition of cell growth in A549 and NCI-H460 cells. It also reports effects in murine melanoma models and changes in Cdc25C, Cdc2, cyclin B1, p53, and p21 pathways. These observations connect sphingolipid depletion with cell cycle regulation and tumor biology. They do not demonstrate clinical anticancer efficacy.

In neuroscience research, SPT is relevant to lipid homeostasis in the hippocampus. The cited postoperative cognitive dysfunction study found increased SPT signal in the hippocampal CA1 region of affected rats. Myriocin was used as an intervention to reverse the metabolic disturbance, which supports pathway involvement in that specific model.

Evidence & Benchmarks

• Myriocin is identified as a selective SPT inhibitor with a reported Ki of 0.28 nM in the product-described biochemical assay; the available product page does not state the assay temperature, buffer, substrate concentrations, or incubation time (product information)
• Myriocin shows dose-dependent inhibition of A549 lung cancer cell growth with a reported IC50 of 30 μM in the product-described cellular assay; the exposure duration and culture conditions are not specified on the product page (product information)
• Myriocin shows dose-dependent inhibition of NCI-H460 lung cancer cell growth with a reported IC50 of 26 μM in the product-described cellular assay; the exposure duration and culture conditions are not specified on the product page (product information)
• In murine melanoma models, the product dossier reports that myriocin suppresses tumor formation; the supplied product description does not provide the mouse strain, dose, treatment schedule, tumor endpoint, or observation period (product information)
• The product dossier associates myriocin treatment with modulation of Cdc25C, Cdc2, cyclin B1, p53, and p21 in tumor-related experiments; the supplied description does not specify the tissue, assay method, or collection time (product information)
• In a rat cardiopulmonary bypass model of postoperative cognitive dysfunction, spatial mass-spectrometry imaging identified lipid accumulation in hippocampal CA1, while immunofluorescence showed increased SPT and reduced iPLA2 signal in affected animals (Zheng et al., Journal of Cerebral Blood Flow & Metabolism)
• In the same rat study, intervention with myriocin and docosahexaenoic acid reduced postoperative cognitive dysfunction incidence and normalized disrupted hippocampal lipid metabolism; the result applies to the reported rat cardiopulmonary bypass model and not directly to human patients (Zheng et al., 2024)

Applications, Limits & Misconceptions

Research applications

• Sphingolipid metabolism research: Use myriocin to test whether a phenotype depends on SPT-mediated de novo lipid synthesis.
• Cancer research: Pair cell-growth measurements with lipid profiling to distinguish pathway inhibition from nonspecific loss of viability.
• Immunology: Use the compound as an immunosuppressive agent in mechanistic experiments, while measuring immune-cell state and viability separately.
• Cell cycle regulation: Assess Cdc25C, Cdc2, cyclin B1, p53, and p21 only in the relevant experimental system and at defined collection times.
• Neurobiology: The cited rat study supports investigating SPT-linked lipid changes in postoperative cognitive dysfunction, but it does not establish a human treatment strategy.

Why this cross-domain matters, maturity, and limitations

Myriocin connects cancer and neurobiology through a shared metabolic target rather than through a shared disease mechanism. Cancer-cell growth assays and the rat postoperative cognitive dysfunction model both implicate SPT-linked lipid metabolism, but they use different organisms, tissues, endpoints, and treatment designs. The evidence is therefore preclinical and model-dependent. The strongest conclusion is that myriocin is a useful perturbation tool for testing SPT involvement. A hypothesis that the same downstream lipid changes explain both tumor growth inhibition and postoperative cognitive dysfunction remains unproven and requires direct comparative experiments.

Common Pitfalls or Misconceptions

• Ki is not an automatic dosing recommendation. The biochemical Ki of 0.28 nM cannot be transferred directly to a cell culture concentration because cellular exposure and assay design alter apparent potency.
• One cell-line IC50 is not a cancer-wide efficacy value. The reported A549 and NCI-H460 results support model-specific growth inhibition, not activity against every tumor type.
• Antiproliferative activity is not proof of a single downstream mechanism. Changes in p53, p21, or cell-cycle proteins should be interpreted with direct measurements of SPT activity and sphingolipid composition.
• Rat POCD findings are not clinical evidence. The cited study used a rat cardiopulmonary bypass model, so translation to human surgery requires independent pharmacology, safety, and efficacy studies.
• A solution is not a permanent stock. The product guidance recommends prompt use of solutions rather than long-term storage, even though the crystalline solid is stored at -20 °C.

Workflow Integration & Parameters

Use myriocin as a controlled pathway perturbation. Record the lot, solvent, preparation date, exposure schedule, and final vehicle concentration. Include a vehicle control and a concentration-response design when the research question concerns cellular potency. A matched untreated control is also useful for separating baseline variation from treatment effects.

Protocol Parameters

• Compound identity: Confirm Myriocin, CAS 35891-70-4, SKU B6064, and the lot-specific certificate before use; the product is typically listed at purity ≥98%, with the exact value requiring lot verification (product information).
• Solvent: The reported solubility is 2 mg/mL in methanol; the product page does not specify the temperature or mixing time for this value, so document the actual preparation conditions used in the laboratory (product information).
• Storage: Store the crystalline solid at -20 °C; protect prepared solutions from prolonged storage and use them promptly according to the product guidance (product information).
• Shipping: Small-molecule shipments are specified for blue-ice conditions; inspect the received material and follow institutional handling procedures before reconstitution.
• Cell assays: Treat the A549 IC50 of 30 μM and NCI-H460 IC50 of 26 μM as reported assay benchmarks, not universal working concentrations; reproduce the exposure duration, medium, cell density, and endpoint before comparing values.
• Mechanistic readouts: Measure a direct sphingolipid endpoint alongside viability or proliferation when claiming SPT-dependent activity; this is a workflow recommendation rather than a dose reported by the cited study.
• Animal-model interpretation: For postoperative cognitive dysfunction experiments, report species, cardiopulmonary bypass procedure, hippocampal region, behavioral endpoint, myriocin schedule, and comparator treatment; the cited article supports the model-level conclusion but does not supply all parameters in the available abstract.

Related reading

Myriocin (SKU B6064): Resolving Lab Challenges in Sphingolipid Research emphasizes workflow reproducibility; this article extends that practical focus by separating biochemical Ki, cellular IC50, and model-specific evidence.

Myriocin: Selective SPT Inhibitor for Sphingolipid Metabolism introduces the pathway role of myriocin; this article clarifies the evidentiary limits of translating that mechanism into oncology or immunology conclusions.

Spatial Metabolomics Unveils Hippocampal Lipid Disruption in POCD summarizes the rat brain study; this article adds explicit benchmark conditions, cross-domain limitations, and a laboratory integration framework.

Conclusion & Outlook

Myriocin is a selective serine palmitoyltransferase inhibitor for experimentally reducing de novo sphingolipid biosynthesis. Its strongest use is as a mechanistic probe. Product-reported biochemical, cellular, tumor-model, and cell-cycle findings support applications in sphingolipid metabolism research and cancer research. The cited rat study adds evidence that SPT-linked lipid disruption accompanies postoperative cognitive dysfunction after cardiopulmonary bypass and that myriocin can improve the reported model phenotype.

Future work should preserve the distinction between enzyme potency, cellular response, and organism-level outcome. Experiments should pair behavioral or growth endpoints with direct lipid measurements and clearly reported exposure conditions. Any hypothesis that SPT inhibition has therapeutic value beyond these preclinical systems requires new pharmacology and disease-specific validation. The current evidence supports careful research use, not clinical substitution.